An upward revision of the blood pressure numbers used to identify risk of end-stage renal disease (ESRD) might actually help doctors provide better care for their patients, said the authors of a study in patients with chronic kidney disease (CKD).
Read more:
Goals for Blood Pressure in Kidney Disease Patients May Be Unrealistic, Suggests Study
The researchers found that systolic blood pressure – the “upper number” in a blood pressure reading – was the key variable. Current guidelines call for CKD patients to maintain a systolic pressure of 130/80 or lower in order to prevent ESRD, which is complete or almost complete kidney failure, leading to dialysis, kidney transplant, or death.
In the study, however, the team determined that systolic pressure had to be 140 or higher in order to be associated with an increased risk of ESRD. A level of 150 or higher was associated with highest risk.
Given that attaining a systolic blood pressure of 130/80 is “very hard to achieve among patients in clinical practice,” it would be worth considering revising the guidelines to make them “a bit more lenient and easier to achieve,” said lead author Carmen A. Peralta, MD, a physician at the San Francisco VA Medical Center (SFVAMC) and an assistant professor of medicine at the University of California, San Francisco (UCSF).
“A revision might allow physicians to not only prescribe fewer blood pressure medications for their patients, but focus more clearly on other aspects of their care, such as blood glucose levels in diabetics,” said Peralta.
The researchers also found, to their surprise, that more than one third of patients in the study had uncontrolled hypertension – defined as a blood pressure of 150/90 or higher – which greatly increases the risk of cardiovascular disease as well as ESRD. The greatest risk factors were being age 60 or older and having high levels of protein in urine.
“The prevalence of hypertension indicates a serious public health concern in the United States,” said Peralta, “and tells us that we need to do a lot more education on the importance of blood pressure control. It also tells us that perhaps our efforts should be focused on reducing blood pressure among people at highest risk, rather than chasing lower numbers in individuals already at 140/90.”
Peralta said that the study, published in the January 9 issue of Archives of General Internal Medicine, is particularly important because it examined the link between blood pressure and risk of ESRD under “real world” conditions in a “contemporary, representative sample” of patients with kidney disease.
She and her fellow researchers studied 16,129 participants in the Kidney Early Evaluation Program (KEEP), a nationwide kidney health screening program offered by the National Kidney Foundation. “The KEEP cohort is a realistic representation of regular people in the United States walking around with CKD,” said Peralta. “In the past, the question of what targets we should establish for preventing ESRD has mostly been studied in randomized control trials, where participants actually tend to be healthier than the general population.”
All study participants had stage 3 CKD, defined as an estimated glomerular filtration rate (eGFR) of lower than 60. GFR is the flow rate of blood filtered by the kidney.
Co-authors of the study are Keith C. Norris, MD, of Charles Drew University of Medicine and Science, Los Angeles, CA; Suying Li, PhD, of Minneapolis Medical Research Foundation, MN; Tara I. Chang, MD and Manjula K. Tamura, MD, of Stanford University School of Medicine; Stacy E. Jolly, MD, of Cleveland Clinic Medicine Institution, OH; George Bakris, MD, of University of Chicago; Peter A. McCullough, MD, of Providence Park Heart Institute, Novi, MI; and Michael Shlipak, MD, of SFVAMC and UCSF.
The study was supported by funds from the National Institute of Diabetes and Digestive and Kidney Diseases, a Robert Wood Johnson Harold Amos award, and the National Institutes of Health. Some of the funds were administered by the Northern California Institute for Research and Education. KEEP is supported by Amgen, Abbot, Novartis, Siemens, Genentech, Genzyme, Nephroceuticals, Pfizer, Lifescan and Suplena.
NCIRE – The Veterans Health Research Institute – is the largest research institute associated with a VA medical center. Its mission is to improve the health and well-being of veterans and the general public by supporting a world-class biomedical research program conducted by the UCSF faculty at SFVAMC.
SFVAMC has the largest medical research program in the national VA system, with more than 200 research scientists, all of whom are faculty members at UCSF.
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.
Provided by University of California, San Francisco (news : web)
See the rest here:
Goals for blood pressure in kidney disease patients may be unrealistic
Just two days after she received a transplant from her preacher, Jennifer Borders seemed well on her way toward recovery. On Mon., Jan.23, the 40-year-old Borders, who suffers from chronic kidney disease, received a transplanted kidney from Derek Staples, pastor of Jacksonville First Baptist Church.
Read this article:
Jennifer Borders recuperating
The family of a Baytown-area boy hopes some of their friends, neighbors and even strangers will join them to raise money for the National Kidney Foundation.
Having a high blood pressure could lead to other medical problems.
See the original post here:
Healthwise: High Blood Pressure and Kidney Disease
A new series of free tools and resources will help community groups increase awareness about steps to prevent kidney disease or improve management. The online resource is sponsored by the National Institutes of Health's National Kidney Disease Education Program (NKDEP).
Read the original post:
NIH kidney disease experts urge: Get Involved
WASHINGTON (Reuters) – U.S. health regulators amended the prescribing label for Merck & Co's cholesterol-lowering drug Vytorin to show it prevents heart problems in patients with chronic kidney disease, but stopped short of approving its use for that purpose. The decision means Merck cannot market Vytorin as a treatment for reducing the rate of heart problems in kidney patients, though it can …
Excerpt from:
FDA label shows Merck cholesterol drug helps heart
DaVita Inc. , a leading provider of kidney care services for those diagnosed with chronic kidney disease today announced it has acquired controlling interest in NephroLife, a leading Bangalore-based kidney care company.
Read more here:
DaVita Acquires Majority Stake in NephroLife India
DaVita Inc. , a leading provider of kidney care services that is committed to improving the quality of life for those diagnosed with chronic kidney disease , announ
View post:
DaVita Way of Giving: Local Clinics Give $1,000,000 to Charities
EUREKA — U.S.
Read the original post:
Thompson visits dialysis center
Levels of certain blood proteins indicate which diabetes patients will likely develop life-threatening kidney problems in the future, according to two studies appearing in an upcoming issue of the Journal of the American Society Nephrology.
More here:
TNF receptors 1 and 2 may predict kidney disease in diabetes
Levels of a natural compound in blood seem to foreshadow high risk of renal failure
See the original post here:
Proteins may warn of diabetic kidney disease risk
The parents of 3-year-old Amelia “Mia” Rivera say a hospital denied a necessary kidney transplant for their daughter because she is already too sick, according to a report from ABC World News.
Originally posted here:
Wolf-Hirschhorn Syndrome Tot Denied Kidney Transplant: What is the Disease?
42-year old David Armond has a genetic kidney disease and has been on dialysis for nearly five years.
Follow this link:
Man uses Craig's List to find kidney donor
( University of Michigan Health System ) Research from the University of Michigan Health System shows the risk for kidney failure among liver transplant recipients is higher following the implementation of Model of End Stage Liver Disease (MELD), a policy change in 2002 that altered how liver transplant allocation is decided.
Read the original here:
U-M News: Kidney failure risk higher for liver transplant patients following policy change
DaVita Inc. , a leading provider of kidney care services for those diagnosed with chronic kidney disease , announced today that it will hold its quarterly conference call to discuss fourth quarter results on Thursday, Feb.
Read more here:
DaVita Inc. Schedules 4th Quarter 2011 Investor Conference Call
HAMBURG, Germany — Evotec AG (TecDAX) today announced a second strategic alliance with Harvard University, this time including Brigham and Women's Hospital aimed at discovering and developing new biomarkers …
Read more here:
Evotec and Harvard University Expand Strategic Alliance Into Kidney Disease
DGAP-News: Evotec AG / Key word(s): AllianceEvotec and Harvard University Expand Strategic Alliance into KidneyDisease17.01.2012 / 07:28Hamburg, Germany – 17 January 2012: Evotec AG (TecDax: EVT) todayannounced a second strategic alliance with …
View original post here:
DGAP-News: Evotec and Harvard University Expand Strategic Alliance into Kidney Disease
A new study by Johns Hopkins researchers published in the January issue of the Journal of the American Geriatrics Society, has revealed that thousands of U.S. senior citizens with kidney disease are good candidates for transplants and would be able to receive them if physicians would overcome past outdated medical biases and put these patients on transplant waiting lists…
Read more:
Vital Transplant Organs Scarce for Seniors
Comedian Jack Black attended the 'Renal Teen Prom' in Sherman Oaks, created for young people with kidney disease.
See the original post here:
Jack Black attends local kidney disease prom